BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Visudyne (Verteporfin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Visudyne (Verteporfin)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03067051-5181@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Visudyne (Verteporfin): Phase 1/2 readout est. (NCT03067051)
DESCRIPTION:Visudyne (Verteporfin)\, phase 1/2.\nStudy: Clinical Study to A
 ssess the Safety and Efficacy of the SpectraCure P18 System\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/verteporfin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03067051
URL:https://assetmemo.bio/drug/verteporfin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807359-5181@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Visudyne (Verteporfin): Phase 1/2 readout est. (NCT06807359)
DESCRIPTION:Visudyne (Verteporfin)\, phase 1/2.\nStudy: Photodynamic Therap
 y of Primary Localized Prostate Cancer With the SpectraCure P18 System\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/verteporfin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06807359
URL:https://assetmemo.bio/drug/verteporfin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381154-5181@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Visudyne (Verteporfin): Phase 2 readout est. (NCT06381154)
DESCRIPTION:Visudyne (Verteporfin)\, phase 2.\nStudy: Photoradiation With V
 erteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresect
 able\, Locally Advanced or Metastatic Pancreatic Cancer\nEstimated primary
  completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/verteporfin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06381154
URL:https://assetmemo.bio/drug/verteporfin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488988-5181@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Visudyne (Verteporfin): Phase 2 readout est. (NCT07488988)
DESCRIPTION:Visudyne (Verteporfin)\, phase 2.\nStudy: SCARFREE-001: Vertepo
 rfin for Scar Prevention\nEstimated primary completion: August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/verteporfin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07488988
URL:https://assetmemo.bio/drug/verteporfin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06306638-5181@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Visudyne (Verteporfin): Phase 1/2 readout est. (NCT06306638)
DESCRIPTION:Visudyne (Verteporfin)\, phase 1/2.\nStudy: Interstitial Photod
 ynamic Therapy Following Palliative Radiotherapy in Treating Patients With
  Inoperable Malignant Central Airway Obstruction\nEstimated primary comple
 tion: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /verteporfin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06306638
URL:https://assetmemo.bio/drug/verteporfin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
